What we do

The Snijder Lab is pioneering multiplexed image-based drug screening in patient biopsies, a technique we call pharmacoscopy, for both systems biology and personalized medicine. In an intervention trial, pharmacoscopy-guided treatments have shown promising improvements in patient outcome for blood cancers (Snijder et al., Lancet Haematology 2017). We now combine these functional drug response profiles with multi-OMICs integration and deep learning-based image analyses, aiming to identify the molecular and cellular systems that underly drug-response individuality and improve patient treatment.

Find out about the Group’s activities


eth zurich

Berend Snijder
Functional Precision Medicine Group
ETH Zurich
Group Webpage


Domain(s) of activity:

  • Systems biology
  • Drug resistance
  • Experimental biology
  • Functional genomics
  • Gene regulatory network analysis
  • Machine learning
  • Oncology
  • Personalised medicine
  • Signaling pathways
  • Single-cell biology
  • Transcriptomics

Domain(s) of application:

  • Basic research
  • Medicine and health